Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
NCT04003519 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2020-06-02
Summary
The purpose of the study is to collect data about predictive factors for the efficacy of Lanreotide Autogel in patients with acromegaly in routine clinical practice.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-30
- Primary Completion
- 2023-06-30
- Completion
- 2023-12-30
More Related Trials
-
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00216398 ·Status: COMPLETED ·Phase: PHASE4
-
Predictive Factors Study
NCT02020499 ·Status: TERMINATED
-
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457 ·Status: COMPLETED ·Phase: PHASE3
-
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
NCT02698384 ·Status: TERMINATED
-
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
NCT00690898 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT01995734 ·Status: APPROVED_FOR_MARKETING
-
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00447499 ·Status: COMPLETED ·Phase: PHASE3
-
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
NCT02396966 ·Status: COMPLETED
-
Acromegaly Combination Treatment Study
NCT01538966 ·Status: TERMINATED ·Phase: NA
-
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00627796 ·Status: COMPLETED ·Phase: PHASE4
-
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233 ·Status: COMPLETED
-
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
NCT01137682 ·Status: COMPLETED ·Phase: PHASE3
-
Somatuline Predictive Factors in Acromegaly and NET
NCT01840449 ·Status: COMPLETED
-
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
NCT00444873 ·Status: COMPLETED ·Phase: PHASE3
-
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
NCT01471405 ·Status: COMPLETED
-
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
NCT05431803 ·Status: COMPLETED
-
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
NCT00446082 ·Status: COMPLETED ·Phase: PHASE1
-
Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00149188 ·Status: COMPLETED ·Phase: PHASE4
-
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00383708 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586 ·Status: COMPLETED
-
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
NCT00600886 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
NCT00225979 ·Status: COMPLETED ·Phase: PHASE3
-
Lanreotide Levels in Acromegaly
NCT00916916 ·Status: UNKNOWN
-
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
NCT00145405 ·Status: COMPLETED ·Phase: PHASE4